This will take effect December 2, 2013

Overview and Clinical Utility:

Effective December 2, 2013, PathGroup will implement in-house testing for Quantitative Kappa & Lambda Free light Chains, Serum. Measurements of free kappa and lambda light chains plays a key role in diagnosis, monitoring, and prognosis for many patients with a monoclonal gammopathy, and are an essential component of the primary screening algorithm for suspected monoclonal plasma cell disorders. Measurement of free light chains can aid in the diagnosis and monitoring of multiple myeloma, lymphocytic neoplasms, Waldenstrom’s macroglobulinemia, amyloid (AL) amyloidosis, and connective tissue diseases such as systemic lupus erythematosus (SLE) in conjunction with other laboratory and clinical findings.

Click Here to read more.